CN1127785A - 一种新的人血小板生成素 - Google Patents
一种新的人血小板生成素 Download PDFInfo
- Publication number
- CN1127785A CN1127785A CN 95110172 CN95110172A CN1127785A CN 1127785 A CN1127785 A CN 1127785A CN 95110172 CN95110172 CN 95110172 CN 95110172 A CN95110172 A CN 95110172A CN 1127785 A CN1127785 A CN 1127785A
- Authority
- CN
- China
- Prior art keywords
- tpo
- sequence
- dna
- cell
- albumen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101000799461 Homo sapiens Thrombopoietin Proteins 0.000 title claims description 10
- 239000013604 expression vector Substances 0.000 claims abstract description 7
- 241000238631 Hexapoda Species 0.000 claims abstract description 5
- 210000004027 cell Anatomy 0.000 claims description 22
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 108091026890 Coding region Proteins 0.000 claims description 3
- 108091092724 Noncoding DNA Proteins 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 230000036252 glycation Effects 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 abstract description 13
- 238000006243 chemical reaction Methods 0.000 abstract description 5
- 241000124008 Mammalia Species 0.000 abstract description 3
- 210000004072 lung Anatomy 0.000 abstract description 3
- 238000012216 screening Methods 0.000 abstract description 2
- 239000002473 artificial blood Substances 0.000 abstract 1
- 210000003754 fetus Anatomy 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 230000001131 transforming effect Effects 0.000 abstract 1
- 102100034195 Thrombopoietin Human genes 0.000 description 51
- 101710113649 Thyroid peroxidase Proteins 0.000 description 51
- 150000001413 amino acids Chemical class 0.000 description 19
- 108020004414 DNA Proteins 0.000 description 15
- 210000001772 blood platelet Anatomy 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 12
- 241000588724 Escherichia coli Species 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 101150077103 TPO gene Proteins 0.000 description 6
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 5
- 108020004511 Recombinant DNA Proteins 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- 230000035800 maturation Effects 0.000 description 5
- 229960000485 methotrexate Drugs 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 210000001501 megacaryocyte Anatomy 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 230000008488 polyadenylation Effects 0.000 description 4
- 241000701447 unidentified baculovirus Species 0.000 description 4
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 description 3
- 241000699802 Cricetulus griseus Species 0.000 description 3
- 101710182846 Polyhedrin Proteins 0.000 description 3
- 102000036693 Thrombopoietin Human genes 0.000 description 3
- 108010041111 Thrombopoietin Proteins 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000008844 regulatory mechanism Effects 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001361 thrombopoietic effect Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 101000694103 Homo sapiens Thyroid peroxidase Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101000966481 Mus musculus Dihydrofolate reductase Proteins 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 102000053400 human TPO Human genes 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000003593 megakaryocyte Anatomy 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000008521 reorganization Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241001367049 Autographa Species 0.000 description 1
- URNZLKFCSUSASH-AIZSJOTASA-N CC[C@@H](C(C)C1)[C@H]2C1C(C)C[C@@H](C)[C@@H](C)CC(CC)CC(C)C2 Chemical compound CC[C@@H](C(C)C1)[C@H]2C1C(C)C[C@@H](C)[C@@H](C)CC(CC)CC(C)C2 URNZLKFCSUSASH-AIZSJOTASA-N 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 101900264058 Escherichia coli Beta-galactosidase Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101000694108 Mus musculus Thyroid peroxidase Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 210000001728 clone cell Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000000627 locus coeruleus Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 208000027889 monkey disease Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 125000002924 primary amino group Chemical class [H]N([H])* 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012882 sequential analysis Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012745 toughening agent Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 241000701366 unidentified nuclear polyhedrosis viruses Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN95110172A CN1095499C (zh) | 1995-04-14 | 1995-04-14 | 一种新的人血小板生成素 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN95110172A CN1095499C (zh) | 1995-04-14 | 1995-04-14 | 一种新的人血小板生成素 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1127785A true CN1127785A (zh) | 1996-07-31 |
CN1095499C CN1095499C (zh) | 2002-12-04 |
Family
ID=5077583
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN95110172A Expired - Lifetime CN1095499C (zh) | 1995-04-14 | 1995-04-14 | 一种新的人血小板生成素 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1095499C (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1058992C (zh) * | 1996-12-25 | 2000-11-29 | 史江 | 一种重组人血小板生成素及其制剂的生产方法 |
-
1995
- 1995-04-14 CN CN95110172A patent/CN1095499C/zh not_active Expired - Lifetime
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1058992C (zh) * | 1996-12-25 | 2000-11-29 | 史江 | 一种重组人血小板生成素及其制剂的生产方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1095499C (zh) | 2002-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Stryjewska et al. | Biotechnology and genetic engineering in the new drug development. Part I. DNA technology and recombinant proteins | |
CN101228275B (zh) | 糖基化的il-7,制备及应用 | |
CN1267453C (zh) | 生物活性提高的人促红细胞生成素的Fc融合蛋白 | |
CN1279059C (zh) | 生物活性提高的人粒细胞集落刺激因子的Fc融合蛋白 | |
CN1602354A (zh) | 人凝血因子ⅶ多肽 | |
CN1020473C (zh) | 编码表现有人粒性巨噬细胞和嗜伊红细胞生长因子活性之多肽的cDNA克隆 | |
CN101031323A (zh) | Gm-csf部分与聚合物的缀合物 | |
CN1150458A (zh) | 用于刺激造血的通式为gm-csf-l-epo或epo-l-gm-csf的杂合分子 | |
CN1399681A (zh) | 在细胞培养物中增强细胞因子产生的方法 | |
CN1095499C (zh) | 一种新的人血小板生成素 | |
CN1684979A (zh) | 糖基化的人干扰素α同种型 | |
CN100336907C (zh) | 重组人血小板生成素/干细胞因子融合蛋白及其制备 | |
CN1191271C (zh) | 干扰素-胸腺肽融合蛋白及其制法 | |
CN1141319C (zh) | 一种在真核细胞中高效表达重组人白细胞介素12的方法 | |
CN1753994A (zh) | 疫苗 | |
CN1232532C (zh) | 成纤维细胞生长因子-2结构类似物,其生产方法及应用 | |
CN1189209C (zh) | 成骨生长肽在促进造血方面的应用 | |
JP5851410B2 (ja) | 組換えビタミンk依存性タンパク質の生成法 | |
CN1150327C (zh) | 用基因工程方法生产红细胞刺激因子/粒细胞集落刺激因子融合蛋白 | |
CN1284798C (zh) | 聚胸腺素-α1、其组合物、其制备方法和应用 | |
CN1219057C (zh) | 具有造血刺激和免疫调节作用的细胞因子cklf-h1a及其变异体cklf-h1b | |
CN1129805A (zh) | 人促血小板生成素变异体、其cDNA克隆表达及检测方法 | |
CN1451040A (zh) | 通过哺乳动物细胞的培养制备人血小板生成素多肽的方法 | |
Fiers | The Future Role in Medicine of Proteins Made by Genetic Engineering | |
CN1304574C (zh) | 适于原核表达系统的重组人促红细胞生成素基因及其表达载体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C53 | Correction of patent for invention or patent application | ||
CB02 | Change of applicant information |
Applicant after: Shenyang Sansheng Pharmaceutical Co., Ltd. Applicant before: Li Weike Applicant before: Yu Kaiwen Applicant before: Liu Fu |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: LI WEIKE; YU KAIWEN; LIU TO: SANSHENG PHARMACY CO., LTD., SHENYANG CITY |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: SHENYANG SANSHENG PHARMACEUTICAL CO. Free format text: FORMER NAME OR ADDRESS: SANSHENG PHARMACY CO., LTD., SHENYANG CITY |
|
CP03 | Change of name, title or address |
Address after: 1 No. 3, ten, road 110027, Shenyang Economic Development Zone, Liaoning, China Patentee after: Shenyang Sunshine Pharmaceutical Co., Ltd. Address before: 110001 No. 110, democracy Road, Heping District, Liaoning, Shenyang Patentee before: Shenyang Sansheng Pharmaceutical Co., Ltd. |
|
C17 | Cessation of patent right | ||
CX01 | Expiry of patent term |
Expiration termination date: 20150414 Granted publication date: 20021204 |